ELV

A month has gone by since the last earnings report for Avantor, Inc. (AVTR). Shares have added about 13% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Avantor due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important drivers. Avantor reported first-quarter 2026 adjusted earnings per share of 17 cents, down 26.1% from the year-ago quarter. However, the bottom line surpassed the Zacks Consensus Estimate by 6.3%. GAAP earnings per share for the quarter was 6 cents, down from 9 cents per share in the prior-year quarter. Revenues totaled $1.58 billion in the reported quarter, flat year over year. The metric beat the Zacks Consensus Estimate by 2.1%. Avantor's foreign currency translation had a positive impact of 4.1%, resulting in a 4.1% sales decline on an organic basis. Laboratory Solutions (VWR Distribution & Services) Net sales in the Laboratory Solutions segment totaled $1.15 billion in the first quarter, down 5% organically year over year. The decline was primarily driven by lower volumes amid continued softness in end markets, particularly in Europe, along with a modest impact from adverse winter weather in the United States. This figure compares with our segmental projection of $1.05 billion. Despite the year-over-year decline, management indicated that the segment is stabilizing, with performance largely in line with expectations. The VWR e-commerce platform showed encouraging trends, with improvements in traffic, conversions and revenues following recent digital upgrades and the relaunch of vwr.com. However, margins were pressured by lower volumes, pricing dynamics and higher freight costs. The company expects growth to improve gradually through 2026, with a return to positive organic growth in the second half. Bioscience Production (Bioscience & Medtech Products - BMP) The Bioscience Production segment reported net sales of $431 million, reflecting a 2% organic decline year over year. The performance exceeded management expectations, supported by strong execution in process chemicals and NuSil. This figure compares with our segmental projection of $557 million. Within the segment, process chemicals delivered double-digit organic gr...

A month has gone by since the last earnings report for Elevance Health (ELV). Shares have added about 12.6% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Elevance Health due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts. ELV Beats Q1 Earnings Estimates on Rising Net Investment Income Elevance Health reported first-quarter 2026 adjusted earnings per share (EPS) of $12.58, which surpassed the Zacks Consensus Estimate by 17.8%. The bottom line rose 5.1% year over year. Operating revenues advanced 1.5% year over year to $49.5 billion. The top line beat the consensus mark by 3.7%. The strong quarterly results benefited on the back of strong growth in premiums. Segment-wise, the Carelon division posted a robust revenue surge, aided by scaling risk-based services, while Health Benefits saw increased premium yields. However, the upside was partly offset by a decline in overall medical membership and an elevated expense level. Medical membership of Elevance Health was around 45.4 million as of March 31, 2026, which dipped 0.9% year over year. The decrease was due to a decline in Medicaid, Medicare Advantage and Commercial Risk-Based membership. The reported figure beat the Zacks Consensus Estimate of 44.1 million and our estimate of 44.2 million. Premiums totaled $41 billion in the quarter under review, which improved 0.3% year over year and surpassed our estimate of $39.6 billion. Product revenues grew 7.2% year over year to $6.2 billion. The metric beat the Zacks Consensus Estimate and our estimate of $6.1 billion. Net investment income rose 29.7% year over year to $765 million. The metric surpassed the consensus mark of $480.6 million and our estimate of $456.6 million. The Adjusted operating margin of 6.5% deteriorated 20 basis points (bps) year over year. Total expenses escalated 3.9% year over year to $47.9 billion in the first quarter, higher than our estimate of $45.5 billion. The year-over-year increase was due to higher benefit expenses, operating expenses and interest expenses. The operating expense ratio came in at 12.8%, which deteriorated 190 bps year over year. The benefit expen...

RICHMOND, Va., May 07, 2026--(BUSINESS WIRE)--Kinsale Capital Group, Inc. (NYSE: KNSL) today announced that Davenport & Company LLC, a leading wealth management and financial advisory services firm, has signed a lease for approximately 100,000 square feet at Kinsale Center, a premier Class A development in Henrico County, Virginia. Davenport & Company will relocate its headquarters to the property, reinforcing its long-standing presence in the Richmond market while positioning the firm for continued growth. Davenport & Company joins other leading organizations at Kinsale Center, including Elevance Health, Kimley-Horn, and Kinsale Capital Group. Kinsale Center, located at West Broad Street and Staples Mill Road, recently completed Phase 1 of the development with a major renovation of the former Anthem office, now Kinsale’s new headquarters. Completion of Phase 1 establishes a foundation for future phases of the project, which envisions a modern, mixed-use environment across 35 acres with high-end architectural finishes, thoughtfully planned residential and commercial amenities, and convenient access to downtown Richmond and surrounding areas. "We’re pleased to welcome Davenport & Company to Kinsale Center," said Michael Kehoe, Chairman, President, and CEO of Kinsale Capital Group. "Davenport has deep roots in Richmond and a strong reputation in the financial services industry. Their decision to establish their headquarters here underscores the appeal of Kinsale Center as a premier destination for leading firms." Davenport & Company selected Kinsale Center for its strategic location and ability to support the firm’s collaborative, client-focused operations. "This move marks an exciting new chapter for Davenport," said Lee Chapman, President and CEO of Davenport & Company. "Richmond has been home for more than 160 years, and Kinsale Center will make it easier for us to connect with our clients. The strong response to our Libbie Avenue client meeting location proved the value of that access—now we’re expanding it at scale." 2000 Maywill, LLC, a subsidiary of Kinsale Capital Group and the building owner, was represented by Jimmy Appich and Gareth Jones of JLL. Davenport & Company was represented by Pope Hackney of 7Hills Advisors. Kinsale Center continues to attract prominent owners and tenants seeking a dynamic and well-connected business environment. The additi...

Performance beat was driven by a 9% increase in Average Selling Price (ASP) to $58,800, resulting from Medicare fee updates and a favorable shift toward international and Medicare Advantage revenue. Management is pivoting the go-to-market strategy from high-cost direct-to-patient advertising to recurring referral sources like rehab hospitals and O&P providers to lower customer acquisition costs. The MyoConnect program has scaled to over 150 referring rehab facilities in nine months, providing higher-quality, pre-qualified patient leads with better medical conversion potential. Market access has expanded significantly from 9 million to 158 million covered lives following the 2024 Medicare coverage milestone and new national contracts with commercial payers like Elevance. International growth reached a Q1 record of approximately $2 million, fueled by favorable insurance environments and statutory health insurance rulings in Germany. Operational leverage improved as revenue grew 3% while operating expenses decreased 1%, supported by a 100 basis point expansion in gross margin. Full-year 2026 revenue guidance is reaffirmed at $43 million to $46 million, with a commitment to limit operating expense growth to half the rate of revenue growth. Q2 revenue is projected between $10.3 million and $10.8 million, assuming a modest increase in advertising spend to build the pipeline for the second half of the year. Gross margins are expected to benefit starting in Q2 from a 10% reduction in material costs following the launch of a mobile app that eliminates the need to ship laptops with devices. The MyoPro 3 next-generation platform is in development, focusing on increased processing power to support future software-driven clinical innovations. Management expects to sign additional state-specific contracts under the Elevance national arrangement over the next several months to further improve authorization rates. Direct billing revenue declined to 71% of total revenue from 79% last year, reflecting the intentional structural shift toward the recurring referral model. Medicare Advantage plans continue to present a challenging macro environment, which the company is mitigating by focusing on in-network patients to secure higher authorization rates. A randomized control trial at the University of Utah is underway with 18 of 50 subjects enrolled; successful completion is expec...

Amwell reported Q1 revenue of $54.9 million, down ~18% year-over-year, but narrowed adjusted EBITDA loss to $3.1M (versus $12.2M a year ago), cut operating expenses ~31%, ended the quarter with roughly $179–182M in cash and no debt, and targets cash-flow breakeven in Q4. The company is pushing a unified telehealth platform focused on payers and government, citing a three-year renewal with Elevance Health and an expected Defense Health Agency (DHA) renewal around July that could later restore an automated behavioral-health program worth an estimated >15–20% of platform value. Management highlighted regulatory tailwinds (permanent Medicare telehealth expansions and new reimbursement codes) and growing demand for AI-enabled care, positioned Amwell as the infrastructure for "agentic AI," while raising full-year adjusted EBITDA guidance to a loss of $16M–$12M with revenue guidance of $195M–$205M. Interested in American Well Corporation? Here are five stocks we like better. Can the New CEO Revive This Struggling Telehealth Stock? American Well (NYSE:AMWL) executives highlighted progress toward profitability and described what they see as rising demand for a unified telehealth platform during the company’s first-quarter fiscal 2026 earnings call. Chairman and CEO Dr. Ido Schoenberg pointed to large customer renewals, government deployments, and a regulatory environment he said is increasingly supportive of telehealth. Schoenberg said the company spent the past year focusing on “solving clear, urgent customer needs” by consolidating around a unified platform. He argued that payers, facing margin pressure as “premiums are not keeping pace with the total cost of care,” are increasingly turning to technology-enabled care and “AI-powered clinical programs” as a cost and outcomes lever. → Roblox Stock Slides to New Low as Safety Changes Weigh on Outlook Doximity is the Facebook and LinkedIn of the Medical Community He also emphasized what he called a key adoption barrier for customers: vendor sprawl and fragmented tech stacks that make it difficult to integrate point solutions and measure performance across programs. Amwell’s approach, he said, is to provide a “trusted, proven technology-enabled care infrastructure” that customers can white label and embed into their own digital front doors, along with unified engagement, navigation, and analytics capabilities. Schoenber...

Image source: The Motley Fool. Tuesday, May 5, 2026 at 5 p.m. ET Chairman & Chief Executive Officer — Ido Schoenberg President & Chief Financial Officer — Mark Hirschhorn Ido Schoenberg: Thank you, operator. Good evening, everyone. Over the past 12 months, we focus on what matters most, solving clear urgent customer needs. We deliver dependable, unified platform, and the market is responding. Elevance renewed for 3 years. DHA deployed globally. Our pipeline is growing. CMS is increasingly making telehealth flexibilities permanent. And in 2025, we reduced losses by $100 million. We also significantly grew our subscription revenue mix. We have ample cash, no debt and a clear path to cash flow breakeven in Q4 with real confidence in multiyear growth beyond it. Amwell entered 2026 with one focus, consolidate our platform and deliver what payer and provider customers need most today and in the future. The market opportunity is real and urgent. Payers are under serious margin pressure. Premiums are not keeping pace with the total cost of care. Technology-enabled care and AI-powered clinical programs, in particular, are now one of the most critical levers payers have. They help control costs. They help improve outcomes. They help payers compete for members and sponsors. This is no longer speculative. It is a survival imperative, but adoption remains hard. Despite strong demand, customers are struggling. Vendor sprawl is a real burden. Legacy tech stacks and internal silos make it expensive to integrate point solutions. The result, fragmented member experiences and very limited visibility into what actually works. Customers cannot easily measure performance across their programs. Switching between them or optimizing member attribution is slow, expensive and painful. That is exactly where we step in. Amwell solves this. We offer a trusted, proven technology-enabled care infrastructure, a unified digital stack that lets health care sponsors act as their own system integrators. Customers white label and embed the clinical programs their members need directly within their own digital front door. They control navigation, they monitor results. And those results go to the heart of their business, lower costs, better outcomes and stronger market share. With Amwell, customers get one unified engagement and navigation platform. It reduces acquisition and retention costs. It m...

Pediatrix Medical Group, Inc. MD reported first-quarter 2026 adjusted earnings per share (EPS) of 44 cents, which beat the Zacks Consensus Estimate by 18.9%. The bottom line increased 33.3% year over year. Net revenues increased 3.9% year over year to $476.2 million. The top line exceeded the Zacks Consensus Estimate by 2%. The strong performance was driven by improved reimbursements, along with contributions from recent acquisitions and better same-unit performance. However, these gains were partly offset by lower patient volumes and slightly higher operating costs. Pediatrix Medical Group, Inc. price-consensus-eps-surprise-chart | Pediatrix Medical Group, Inc. Quote Same-unit revenues increased 2.8% year over year, beating the Zacks Consensus Estimate. Same-unit revenues from patient service volumes declined 1.6% year over year. Same-unit revenues from net reimbursement-related factors grew 4.4% year over year. This growth was supported by improved cash collections, higher administrative fees from hospital contracts, more patient cases and a slightly better payor mix. This metric exceeded both the Zacks Consensus Estimate and our model estimate of 1%. Total operating expenses were $434.5 million, up 1.9% year over year. The figure was higher than our estimate of $426.1 million. The year-over-year increase was primarily due to higher depreciation and amortization and general and administrative expenses. Practice salaries and benefits totaled $345.7 million, up 2.6% year over year, mainly due to higher same-unit clinical salary expenses. Interest expense decreased 9.7% year over year to $8.3 million. The figure was below our estimate of $8.9 million due to lower interest rates and borrowings. Adjusted EBITDA rose 18.3% year over year to $58.2 million, driven by favorable same-unit performance and contributions from recent acquisitions. Pediatrix Medical exited the first quarter of 2026 with cash and cash equivalents of $205.8 million, down from $375.2 million as of Dec. 31, 2025. There were no outstanding borrowings on its revolving credit facility at the end of the quarter. Total assets of $2.1 billion decreased from $2.2 billion at the end of 2025. Total debt, including finance leases, net was $590.8 million, which fell from $597.3 million at the end of 2025. Total shareholders’ equity of $878.6 million improved from $865.9 million at the end of 2025. Oper...

Select Medical Holdings Corporation SEM reported first-quarter 2026 adjusted earnings per share (EPS) of 36 cents, which missed the Zacks Consensus Estimate by 16.3%. The bottom line declined 18.2% year over year. Net operating revenues advanced 5% year over year to $1.4 billion. The top line beat the consensus mark by 1.5%. The quarterly earnings suffered due to an elevated expense level and a decline in patient days, exerting pressure on profitability in the Critical Illness Recovery Hospital segment. However, the downside was partially offset by solid revenue growth in the Rehabilitation Hospital segment, driven by higher admissions and improved occupancy. Select Medical Holdings Corporation price-consensus-eps-surprise-chart | Select Medical Holdings Corporation Quote Total costs and expenses were $1.3 billion, which increased 6.7% year over year and came higher than our estimate by 1.4%. The year-over-year rise was due to higher costs of services, exclusive of depreciation and amortization, and general and administrative expenses. Adjusted EBITDA declined 6.5% year over year to $141.6 million but beat our estimate of $141.1 million. The segment recorded revenues of $638.8 million in the first quarter, which grew 0.3% year over year, but missed the Zacks Consensus Estimate and our estimate of $671.3 million. The unit benefited on the back of a 1% year-over-year increase in admissions and a 2.5% rise in revenue per patient day. Patient days slipped 2.2% year over year. The occupancy rate deteriorated 140 bps year over year to 72%. Adjusted EBITDA declined 15.3% year over year to $73.4 million and fell short of the consensus mark and our estimate of $88.7 million. The adjusted EBITDA margin of 11.5% deteriorated 210 bps year over year. SEM’s Rehabilitation Hospital segment remained the primary growth engine. The unit’s revenues rose 14.5% year over year to $351.9 million, which surpassed the Zacks Consensus Estimate and our estimate of $320.8 million. The favorable performance stemmed from year-over-year increases of 13% and 12.5%, respectively, in admissions and patient days. The occupancy rate was 83%, which improved 120 bps year over year in the quarter under review. Adjusted EBITDA improved 15.1% year over year to $81.1 million, which beat the consensus mark and our estimate of $69.4 million. The adjusted EBITDA margin of 23% improved 10 bps year over...

Acadia Healthcare Company, Inc. ACHC reported adjusted first-quarter earnings of 37 cents per share, which beat the Zacks Consensus Estimate of 28 cents. However, the bottom line declined 7.5% year over year. Total revenues increased 7.6% year over year to $828.8 million. The top line beat the consensus mark of $824 million. The better-than-expected quarterly results were driven by increased patient days and revenues per patient day, and higher admissions, which were partially offset by lower average length of stay and higher expenses. Acadia Healthcare Company, Inc. price-consensus-eps-surprise-chart | Acadia Healthcare Company, Inc. Quote ACHC’s top line benefited most from its Acute Inpatient Psychiatric Facilities business, where revenues increased 14% year over year to $470.7 million and beat the Zacks Consensus Estimate by 6.4%. The metric benefited from higher volumes, aided by expanded capacity from both new construction and additions at existing facilities. Specialty Treatment Facilities’ revenues declined 6.5% from the prior-year period to $128.1 million. Comprehensive Treatment Facilities’ revenues rose 2.5% year over year to $140.4 million, while Residential Treatment Facilities’ revenues increased 6.3% to $89.6 million. Same-facility revenues of $813.4 million rose 7.3% year over year and beat the Zacks Consensus Estimate by 2%. The year-over-year improvement was driven by a 1.6% increase in patient days. Admissions grew 6.5% year over year. The average length of stay declined 4.6% year over year and missed the consensus estimate by 5.5%. Revenue per patient day increased 5.6% year over year. In the overall facility, patient days improved 1.5% year over year, while admissions grew 7.8%. Revenue per patient day increased 5.9% year over year. The average length of stay declined 5.8% year over year. Total expenses of $817.8 million rose from $757 million in the prior-year period due to higher salaries, wages and benefits, other operating expenses, supply costs and professional fees. Total adjusted EBITDA rose 7.5% year over year to $144.2 million. During the quarter, the company added 82 newly licensed beds, including 42 beds at existing facilities and 40 beds from newly constructed facilities, including a joint venture with Tufts Medicine. Acadia Healthcare exited the first quarter with cash and cash equivalents of $158.5 million, which increased...

Teladoc Health, Inc. TDOC reported a first-quarter 2026 adjusted loss of 36 cents per share, missing the Zacks Consensus Estimate of a 32-cent loss. This marks an improvement from a loss of 53 cents per share in the same quarter last year. Operating revenues declined 2% year over year to $613.8 million but modestly exceeded the consensus estimate by 0.3%. The quarterly results were primarily impacted by weakness in the BetterHelp segment and declining subscription revenues, which were partially offset by strength in the Integrated Care segment, international growth and cost efficiencies. Teladoc Health, Inc. price-consensus-eps-surprise-chart | Teladoc Health, Inc. Quote Revenues from access fees totaled $484.7 million, down 8% year over year. The figure missed the Zacks Consensus Estimate of $506.5 million as well as our estimate of $506.9 million. Other revenues increased 25% year over year to $129.2 million. The metric beat the Zacks Consensus Estimate of $106.7 million and our estimate of $106.1 million. On a geographical basis, Teladoc Health generated $491.5 million in revenues from the United States, down 6% year over year. The metric lagged the Zacks Consensus Estimate of $502 million. International revenues of $122.3 million advanced 17% year over year in the quarter and surpassed the consensus mark of $111 million. Adjusted EBITDA rose 0.1% year over year to $58.2 million and beat our estimate of around $50.5 million. Total costs and expenses of $675.6 million declined 9.9% year over year and were below our estimate of $679.8 million. The year-over-year decrease was primarily due to goodwill impairment and lower advertising and marketing and general and administrative expenses. The Integrated Care segment’s revenues increased 2% year over year to $395.4 million in the reported quarter. The figure beat the Zacks Consensus Estimate of $391.8 million and our estimate of $390.3 million. Adjusted EBITDA rose 12% year over year to $56.3 million and surpassed the consensus mark of $52.3 million. The adjusted EBITDA margin expanded 130 basis points (bps) year over year to 14.2%. The BetterHelp segment generated revenues of $218.4 million, down 9% year over year. The metric missed our estimate of $222.7 million. Adjusted EBITDA declined 75% year over year to $1.9 million. The figure missed the consensus mark of $2.8 million. The adjusted EBITDA margin of 0....

The Cigna Group CI reported first-quarter 2026 adjusted earnings per share (EPS) of $7.79, which beat the Zacks Consensus Estimate by 2.2%. The bottom line improved 15.6% year over year. Adjusted revenues grew 4.7% year over year to $68.5 billion. The top line beat the consensus mark by 2.7%. The quarterly results were aided by the strong Evernorth Health Services segment as a result of expanding membership base and higher specialty volumes. However, the upside was partly offset by rising pharmacy costs and a sharp revenue decline in Cigna Healthcare due to the Health Care Services Corporation (HCSC) transaction. The Cigna Group price-consensus-eps-surprise-chart | The Cigna Group Quote Cigna’s medical customer base came in at 18.3 million as of March 31, 2026, which inched up 1.6% year over year and surpassed the Zacks Consensus Estimate of 18.1 million. The metric benefited on the back of well-performing Middle, Select and International markets. Total benefits and expenses of $66.1 billion increased 4% year over year in the quarter under review due to a rise in pharmacy and other service costs. The adjusted SG&A expense ratio improved 100 basis points (bps) year over year to 4.8%, resulting from a shift in business mix and better operational efficiency. Adjusted income from operations totaled $2.1 billion, which advanced 12% year over year, attributable to higher contributions from the Cigna Healthcare and Evernorth Health Services segments. Evernorth Health Services: The unit’s adjusted revenues rose 9% year over year to $58.4 billion in the first quarter as a result of drug mix in the Pharmacy Benefit Services business, and improved specialty volumes in the Specialty and Care Services business. The metric outpaced the Zacks Consensus Estimate of $56.6 billion. Adjusted operating income, on a pre-tax basis, came in at $1.47 billion, which inched up 2% year over year and marginally beat the consensus mark of $1.45 billion. The metric was aided by solid organic growth in specialty businesses. However, the pre-tax margin deteriorated 20 bps year over year to 2.5%. Cigna Healthcare: The segment recorded adjusted revenues of $11.5 billion, which dropped 21% year over year in the quarter under review. The metric suffered due to the HCSC transaction. Pre-tax adjusted operating income improved 18% year over year to $1.5 billion, higher than the Zacks Consensus Es...

Optune PAX received FDA approval and a U.S. launch, with 868 healthcare providers certified in seven weeks, 169 prescriptions received and 83 patients on therapy at quarter end, and early payer coverage from Elevance Health—management called initial uptake encouraging. Financially, Q1 net revenue was $174 million (up 12% YoY) and NovoCure raised full‑year revenue guidance to $690–$710 million; the company reported a net loss of $71 million (or $28M excluding a one‑time share‑based comp), updated Adjusted EBITDA guidance to −$15M to breakeven, and held $432 million in cash. PANOVA‑4 met its primary endpoint with a 74% disease control rate in metastatic pancreatic cancer, NovoCure is exploring combinations with KRAS inhibitors showing preclinical synergy, and the next major catalyst is top‑line TRIDENT GBM data expected in Q2. Interested in NovoCure Limited? Here are five stocks we like better. NovoCure (NASDAQ:NVCR) reported first-quarter 2026 results highlighted by double-digit year-over-year growth in both active patients and net revenue, driven in part by strength outside the U.S. and an early commercial ramp for its newly approved pancreatic cancer therapy. Executive Chairman Bill Doyle said the company had “a strong start to the year,” pointing to progress on profitability and multiple expected catalysts later in 2026. The biggest development in the quarter was the FDA approval and U.S. launch of Optune PAX for patients with locally advanced pancreatic cancer. Doyle said physician feedback has been positive since PANOVA-3 data were presented and published at ASCO last year, noting “broad recognition” of outcomes including extensions in overall survival and time to pain progression. → Palantir Is Down 30%: Noise? Or a Signal to Accumulate? NovoCure received FDA approval on Feb. 11. In the seven weeks between approval and quarter end, the company said it certified 868 healthcare providers, including 27 prescribers in academic centers—an area where the company historically saw slower TTFields adoption. Through March 31, NovoCure reported: 169 prescriptions received 90 patient starts completed 83 patients on therapy at quarter end, with a “backlog of starts in the funnel” On reimbursement, the company highlighted its first major payer coverage policy for Optune PAX with Elevance Health, which it said covers more than 30 million lives. Management cautioned th...